Peter Fasching
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (42)
Background Wearables and smart devices could complement face-to-face prenatal care appointments by monitoring pregnant women's health, especially since pregnancy may be a vulnerable time when mental health issues and pregnancy-related anxiety may arise. Aim The aim of this study was to analyze the extent whether the willingness of women to use smart devices for pregnancy care monitoring differs between those with pregnancy-related anxiety and those without. Methods A survey was conducted to ascertain participant's general characteristics, attitudes toward smart devices, the willingness to use them, and the level of pregnancy-related anxiety (PRAQ-R2). Associations between the willingness and pregnancy-related anxiety parameters were analyzed. Results Completed questionnaires from 210 women were included in the analysis. A significant difference between women showing high and low levels of pregnancy-related anxiety was observed in terms of their willingness to use a smartwatch (median score 4.00; interquartile range (IQR) 4.00–5.00 vs. 4.00; IQR 3.00–4.00; P = .02), smart contraction counter (median score 4.00; IQR 3.00–5.00 vs. 3.00; IQR 3.00–4.00; P = .02), smart blood pressure monitor (median score 5.00; IQR 3.00–5.00 vs. 4.00; IQR 3.00–4.00; P = .003) or sleep tracker (median score 4.00; IQR 3.00–5.00 vs. 3.00; IQR 2.00–4.00; P = .007). Overall, anxious women showed significantly higher willingness to use smart devices in the context of prenatal care. Conclusions The data suggest that pregnant women are receptive to using smart devices to enhance their prenatal care, particularly those experiencing higher levels of anxiety. This study serves as an initial step in evaluating attitudes toward these devices. As a follow-up, it is recommended that acceptance and feasibility studies are conducted alongside the further development of existing and new pregnancy-specific wearables.
Year:
2026
IDFS by HER2 IHC score at definitive surgery (derived from samples used for eligibility and exploratory purposes). IDFS, invasive disease-free survival; IHC, immunohistochemistry; T-DM1, trastuzumab emtansine.
Year:
2025
Kaplan–Meier curves of OS in ( A ) main tumor groups ( n = 582)—MBOT, MOC, LGI, and UGI; ( B ) patients with MOC by FIGO stage ( n = 184); ( C ) patients with MOC by pattern of invasion in all stages ( n = 178); and ( D ) patients with stage I MOC ( n = 134), by pattern of invasion.
Year:
2025
HER2, PD-L1, and Five-Gene Signature Quartile Analysis. IDFS by HER2 gene expression quartile (A) in the trastuzumab arm; and (B) in the T-DM1 arm; (C) treatment effect on IDFS by HER2 gene expression quartile; (D) effect of HER2 gene expression quartile on IDFS; IDFS by PD-L1 gene expression quartile (E) in the trastuzumab arm; and (F) in the T-DM1 arm; (G) treatment effect on IDFS by PD-L1 gene expression quartile; (H) effect of PD-L1 gene expression quartile on IDFS; IDFS by five-gene signature (i.e., PD-L1/granzymeB/CD8/IFNγ/CXCL9) gene expression quartile (I) in the trastuzumab arm; and (J) in the T-DM1 arm; (K) treatment effect on IDFS by five-gene signature gene expression quartile; (L) effect of five-gene signature gene expression quartile expression on IDFS. Each expression quartile (quartile 2, quartile 3, and quartile 4) is compared to the lowest quartile (quartile 1). The analyses are unstratified and adjusted using a Cox regression model that includes percent tumor in marked area, clinical stage at presentation, hormone receptor status, type of preoperative HER2-directed therapy, and pathologic nodal status. HER2, human epidermal growth factor receptor 2; IDFS, invasive disease-free survival; IFNγ, interferon gamma; Q, quartile; T-DM1, trastuzumab emtansine.
Year:
2025
Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.
Year:
2025
Comparison of HER2 expression intensity in paired pre-NAT (i.e., before surgery) and post-NAT surgical samples. HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NAT, neoadjuvant therapy.
Year:
2025
Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis ( n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.
Year:
2025
Comparison of IDFS outcomes in the ITT population compared to the (A) RNA-evaluable population (REP) (including pre- and post-NAT surgical samples) and in patients with (B) pre-NAT REP samples (left) or post-NAT surgical REP samples (right). HER2, human epidermal growth factor receptor 2; IDFS, invasive disease-free survival; IHC, immunohistochemistry; ITT, intent-to-treat; NAT, neoadjuvant therapy; T-DM1, trastuzumab emtansine.
Year:
2025
Comparison of baseline patient and disease characteristics assessed at eligibility in the ITT population versus in those with mRNA data derived from pre-NAT or post-NAT surgical samples (RNA-evaluable population). Note: the pre-NAT and post-NAT samples are not paired.
Year:
2025
Comparison of pre-NAT and post-NAT surgical RNA-evaluable samples. (A) ERBB2 (i.e., HER2), CD274 (i.e., PD-L1), checkpoint inhibitor signature (i.e., PD-L1/PD-L2/IDO), CD8A (i.e., CD8), TEFF signature CD8/granzymeA/granzymeB/perforin/IFNγ), three-gene signature (i.e., PD-L1/IFNγ/CXCL9), five-gene signature (i.e., PD-L1/granzymeB/CD8/IFNγ/CXCL9), Th1 cytokine signature (i.e., CXCL9/CXCL10/CXCL11), and B cell gene expression. (B) Frequency of AIMS PAM50 subtypes overall and by hormone receptor status. (C) Frequency of AIMS PAM50 subtypes by level of HER2 protein expression assessed by IHC in pre- and post-NAT samples. (D) Frequency of AIMS PAM50 subtypes by level of HER2 gene expression in pre- and post-NAT samples. (E) Hallmark gene sets enriched for genes upregulated in post-NAT surgical versus pre-NAT samples (adjusted P
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (100)
Charlie Gourley
University of Edinburgh
Carsten Denkert
Philipps-Universität Marburg
Sue K. Park
Professor
Seoul National University College of Medicine
Eric Hahnen
-
Kathryn Terry
Co-Scientific Director
Boston Children's Hospital
Elizabeth Christie
Peter MacCallum Cancer Institute
Timothy Budden
Lecturer
University of Liverpool
Beth Karlan
Vice Chair
University of California, Los Angeles
Anna Jakubowska
Head
Pomeranian Medical University
Lynne Wilkens
Professor
University of Hawaii at Manoa
Anthony Swerdlow
Professor of Epidemiology
Institute of Cancer Research Sutton
Patrick Neven
University Hospitals Leuven
Sherene Loi
University of Melbourne
Matthew Wakefield
University of Melbourne
Martin Widschwendter
Professor; Director
University of Innsbruck
P. M. Webb
Group Leader
QIMR Berghofer Medical Research Institute
Martin Köbel
Associate Professor
University of Calgary
Estrid V. Hoegdall
University of Copenhagen
Paul Timpson
Co-Director ACRF (INCITe) Centre
Garvan Institute of Medical Research
James D Brenton
University of Cambridge
Jae-Weon Kim
Professor
Seoul National University Hospital
Peter Sinn
Head, Division of Gynaecopathology
University Hospital
Zbigniew Nowecki
Head od Department
Maria Sklodowska-Curie National Research Institute of Oncology
Charles Edward Geyer Jr
Professor of Medicine in Division of Hematology/Medical Oncology
University of Pittsburgh
Cezary Cybulski
Pomeranian Medical University
Lyndal Anderson
University of Western Sydney
Sabine Kasimir-Bauer
University Hospital Essen
Claus Høgdall
Professor in Clinical Gynecologic Oncology
University of Copenhagen
Hanna Huebner
University Hospital Erlangen
Lindsay J Collin
Assistant Professor
Emory University
Gabriel N. Hortobagyi
The University of Texas MD Anderson Cancer Center
Christine Solbach
Goethe University Frankfurt
Judith Balmaña
Head
Hospital Universitari Vall d'Hebron
Heike Leutheuser
Professor of Ambient Assisted Living & Medical Assistance Systems at University of Bayreuth
University of Bayreuth
Anthony Gill
University of Sydney
Linda Cook
Professor
University of Colorado Cancer Center
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Parham Minoo
Associate Clinical Professor of Pathology
University of Calgary
Angela Brooks-Wilson
Simon Fraser University
Tomasz Kluz
Professor
Rzeszów University
Joellen Schilkdraut
Professor
Emory University
Mark Basik
McGill University
Francois-Clement Bidard
Professor of Medical Oncology
Institut Curie
Michael Anglesio
Associate Professor
The University of British Columbia
Ramona Erber
W2-Professorin, Oberärztin
University of Regensburg
Nicholas Hawkins
Emeritus Professor
UNSW Sydney
Usha Menon
Professor of Gynaecological Oncology
University College London
Terence Williams
City Of Hope National Medical Center
Nadia Harbeck
-
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Judith Lea Lindner
-
Kelly K Hunt
Chair
The University of Texas MD Anderson Cancer Center
Dennis J. Slamon
University of California, Los Angeles
Tanja Fehm
Professor
University Hospital Düsseldorf
Peter Schmid
Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute
Sandra Orsulic
Professor
University of California, Los Angeles
Cheng-Han Lee
Associate Professor
University of Alberta
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Jae-Hoon Kim
Yonsei University College of Medicine
Anna H. Wu
Professor
University of Southern California
C Blake Gilks
-
Thomas Karn
Goethe University Frankfurt
Francesmary Modugno
University of Pittsburgh
Swati Kulkarni
Professor of Surgery
Northwestern University
Alexander Hein
-
Kylie-Ann Mallitt
Senior Lecturer in Biostatistics
University of Sydney
Dale Garsed
University of Melbourne
Philip Crowe
Professor Surgery
University of New South Wales
Renée Fortner
Head of Division
Deutsches Krebsforschungszentrum
K Sundfeldt
Professor/Consultant
University of Gothenburg, Sahlgrenska Academy
Tomasz Huzarski
Pomeranian Medical University
Byoung-Gie Kim
Sungkyunkwan University School of Medicine
Guillermo Villacampa Javierre
Biostatistician
Vall d´Hebron Institute of Oncology
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Dane Cheasley
Senior Research Fellow
University in Western Australia
Gregg Nelson
Gynecologic Oncologist
University of Calgary
Sara Hurvitz
Professor, Division Head
Washington University School of Medicine
Changxian Shen
City of Hope
Jennifer Anne Doherty
Professor
University of Utah
Peter Lucas
Professor and Vice Chair of Research
Mayo Clinic
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Brenda Y Hernandez
University of Hawaii
Michael Edwin Jones
Senior Staff Scientist
Institute of Cancer Research
Kylie L Gorringe
Group Leader
Peter MacCallum Cancer Institute
Jan Lubiński
Head of Dept
Pomeranian Medical University
Mona El-Bahrawy
Imperial College London
Aleksandra Gentry-Maharaj
University College London
Miguel Martin
Universidad Complutense de Madrid
Violeta Serra
Group Leader
Vall d'Hebron Institute of Oncology
Manali Bhave
Assistant Professor
Winship Cancer Institute of Emory University
David G. Huntsman
The University of British Columbia
Janusz Menkiszak
Head of the University Clinic
Pomeranian Medical University
Eva M. Ciruelos-Gil
Universidad Complutense de Madrid
Clare Scott
Walter and Eliza Hall Institute of Medical Research
Susan Ramus
Professor of Molecular Oncology
University of New South Wales
Paul Jank
Head of Translational Research Laboratory
-
Paul Cohen
University of Western Australia
Aline Talhouk
Assistant Professor
The University of British Columbia
David Lawson Morris
Professor of Surgery
University of New South Wales
Make your next move.
Prepare your application
Review drafts before you send them.